See also this year's filing and all EDGAR filings for this company.
PDF Report 0001785345_2023_Landos_Biopharma_Inc.pdf
Logs
| info | NetIncome node detected by revenue/expenses heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'OperatingIncomeLoss'} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 2': 2, '100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)': 8}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001785345, Landos Biopharma Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 45,253,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 0 |
| 3 | remainder_Assets | 0 |
| 4 | LiabilitiesCurrent | 6,122,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 14,881,000 |
| 9 | ResearchAndDevelopmentExpense | 25,680,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | 1,453,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 45,253,000 |
| 1 | Liabilities | 6,122,000 |
| 2 | Expenses | 40,561,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 39,131,000 |
| 5 | NetIncome | -40,561,000 |
| 6 | ComprehensiveNetIncome | -39,834,500 |
| 7 | BaseVar | 46,694,500 |
| 8 | EconomicCapitalRatio | 1.07 |
Edgar->Model Mapping
Feature Distribution
Change over Time
